Table 1.

Demographics and baseline characteristics

Patients with CT and FDG-PET evaluable lesions
(n = 51)a
Median age (range)61 (47–78)
Sex, n (%)
 Male30 (58.8)
 Female21 (41.2)
Race, n (%)
 White44 (86.3)
 Asian or Pacific islander3 (5.9)
 Black1 (2.0)
 Not available3 (5.9)
ECOG PS, n (%)
 015 (29.4)
 129 (56.9)
 27 (13.7)
Smoking history, n (%)
 Never smoked5 (9.8)
 Previously smoked35 (68.6)
 Current smoker11 (21.6)
Histology
 Adenocarcinoma37 (72.5)
 Squamous carcinoma8 (15.7)
 Large-cell carcinoma1 (2.0)
 Other (including NOS)5 (9.8)
Prior Therapies
 Radiotherapy32 (62.7)
 Surgery50 (98.0)
 Systemic51 (100)
Time since initial diagnosis, median (range) in months15.0 (2–98)
EGFR mutation status, n (%)(n = 35)b
 Sensitizing mutant4 (11.4)
 Wild type30 (85.7)
KRAS mutation status, n (%)(n = 35)b
 Mutated7 (20.0)
 Wild type27 (77.1)
CT target lesions, median (range)
 Number3 (1–5)
 Size, mm24 (11–78)
FDG-PET target ROIs, median (range)
 Number3 (1–5)
 FDG uptake (SUVmax)5.63 (1.6–31.7)c
FLT-PET target ROIs, median (range)
 Number3 (1 – 5)
 FLT uptake (SUVmax)2.5 (1.0–12.2)c

Abbreviations: IHC, immunohistochemistry; NOS, not otherwise specified

  • aTwo patients received FDG without FLT and one received FLT without FDG. Hence, the total number of patients with or without FLT scans is 50.

  • bThirty-five patients had available tissue. However, for 1 patient, tissue was deemed unevaluable for KRAS mutation status.

  • cMedian SUVmax values reflect values corrected for lean body mass in each patient, whereas the range for individual lesions reflects the raw SUVmax value on the basis of the mean value obtained from clustering of the most intense voxel and the 6 voxels surrounding it. The median uncorrected SUVmax for lean body mass was 8.8 for FDG-PET and 4.2 for FLT-PET.